Perdagangan DiaMedica Therapeutics Inc. - DMAC CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.1118 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.030779% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.013666% | ||||||||
Waktu biaya inap | 22:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | 1.3304 |
Open* | 1.2711 |
1-Year Change* | -54.77% |
Day's Range* | 1.2711 - 1.4676 |
52 wk Range | 1.12-3.23 |
Average Volume (10 days) | 44.41K |
Average Volume (3 months) | 1.29M |
Market Cap | 36.76M |
P/E Ratio | -100.00K |
Shares Outstanding | 26.44M |
Revenue | N/A |
EPS | -0.50 |
Dividend (Yield %) | N/A |
Beta | 1.76 |
Next Earnings Date | Mar 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 1.3791 | 0.0884 | 6.85% | 1.2907 | 1.4676 | 1.2711 |
Feb 7, 2023 | 1.3304 | 0.0686 | 5.44% | 1.2618 | 1.3502 | 1.2222 |
Feb 6, 2023 | 1.2915 | 0.0303 | 2.40% | 1.2612 | 1.3007 | 1.2612 |
Feb 3, 2023 | 1.3208 | 0.0201 | 1.55% | 1.3007 | 1.3402 | 1.2608 |
Feb 2, 2023 | 1.3501 | 0.0497 | 3.82% | 1.3004 | 1.3501 | 1.2619 |
Feb 1, 2023 | 1.3205 | -0.0096 | -0.72% | 1.3301 | 1.3502 | 1.2905 |
Jan 31, 2023 | 1.3205 | -0.0479 | -3.50% | 1.3684 | 1.3886 | 1.3198 |
Jan 30, 2023 | 1.3696 | -0.0680 | -4.73% | 1.4376 | 1.4378 | 1.3691 |
Jan 27, 2023 | 1.4285 | 0.0597 | 4.36% | 1.3688 | 1.4382 | 1.3688 |
Jan 26, 2023 | 1.4086 | -0.0188 | -1.32% | 1.4274 | 1.4871 | 1.3691 |
Jan 25, 2023 | 1.4871 | 0.0400 | 2.76% | 1.4471 | 1.4969 | 1.4274 |
Jan 24, 2023 | 1.4868 | 0.0001 | 0.01% | 1.4867 | 1.5163 | 1.4867 |
Jan 23, 2023 | 1.5163 | 0.0888 | 6.22% | 1.4275 | 1.5166 | 1.4273 |
Jan 20, 2023 | 1.5165 | 0.0602 | 4.13% | 1.4563 | 1.5360 | 1.4272 |
Jan 19, 2023 | 1.5066 | 0.0793 | 5.56% | 1.4273 | 1.5361 | 1.4273 |
Jan 18, 2023 | 1.5357 | 0.0103 | 0.68% | 1.5254 | 1.5946 | 1.4565 |
Jan 17, 2023 | 1.5851 | 0.0101 | 0.64% | 1.5750 | 1.6046 | 1.5453 |
Jan 13, 2023 | 1.5850 | 0.0297 | 1.91% | 1.5553 | 1.5948 | 1.5552 |
Jan 12, 2023 | 1.5654 | 0.0494 | 3.26% | 1.5160 | 1.5655 | 1.5160 |
Jan 11, 2023 | 1.5459 | -0.0195 | -1.25% | 1.5654 | 1.5753 | 1.4961 |
DiaMedica Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0.5 | 0 | 0 | 0 |
Total Operating Expense | 2.48146 | 4.519 | 7.261 | 11.593 | 12.699 | 13.646 |
Selling/General/Admin. Expenses, Total | 0.71805 | 1.313 | 2.739 | 3.693 | 4.389 | 4.881 |
Research & Development | 1.7612 | 3.206 | 4.522 | 7.9 | 8.31 | 8.765 |
Depreciation / Amortization | 0.00221 | |||||
Operating Income | -2.48146 | -4.519 | -6.761 | -11.593 | -12.699 | -13.646 |
Interest Income (Expense), Net Non-Operating | 0.06302 | 0.009 | -0.039 | 0 | ||
Other, Net | 0.21761 | 0.25 | 1.146 | 0.975 | 0.434 | 0.082 |
Net Income Before Taxes | -2.20083 | -4.26 | -5.654 | -10.618 | -12.265 | -13.564 |
Net Income After Taxes | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Net Income Before Extra. Items | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Net Income | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Income Available to Common Excl. Extra. Items | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Income Available to Common Incl. Extra. Items | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Diluted Net Income | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Diluted Weighted Average Shares | 4.73575 | 5.93579 | 7.74352 | 11.9877 | 15.6803 | 20.7734 |
Diluted EPS Excluding Extraordinary Items | -0.46944 | -0.71768 | -0.74049 | -0.88833 | -0.78391 | -0.6543 |
Diluted Normalized EPS | -0.46944 | -0.71768 | -0.74049 | -0.88833 | -0.78391 | -0.6543 |
Revenue | 0 | 0.5 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 3.619 | 3.365 | 3.416 | 3.246 | 3.536 |
Selling/General/Admin. Expenses, Total | 1.213 | 1.209 | 1.084 | 1.375 | 1.562 |
Research & Development | 2.406 | 2.156 | 2.332 | 1.871 | 1.974 |
Operating Income | -3.619 | -3.365 | -3.416 | -3.246 | -3.536 |
Other, Net | 0.004 | 0.098 | -0.027 | 0.007 | 0.035 |
Net Income Before Taxes | -3.615 | -3.267 | -3.443 | -3.239 | -3.501 |
Net Income After Taxes | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Net Income Before Extra. Items | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Net Income | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Income Available to Common Excl. Extra. Items | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Income Available to Common Incl. Extra. Items | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Diluted Net Income | -3.622 | -3.274 | -3.45 | -3.246 | -3.508 |
Diluted Weighted Average Shares | 18.7667 | 18.7862 | 19.0357 | 26.5021 | 26.4431 |
Diluted EPS Excluding Extraordinary Items | -0.193 | -0.17428 | -0.18124 | -0.12248 | -0.13266 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.193 | -0.17428 | -0.18124 | -0.12248 | -0.13266 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 1.85356 | 1.494 | 17.972 | 8.836 | 27.921 | 45.439 |
Cash and Short Term Investments | 1.73636 | 1.353 | 16.823 | 7.878 | 27.507 | 45.112 |
Cash | 1.73636 | 1.353 | 16.823 | 3.883 | 7.409 | 4.707 |
Total Receivables, Net | 0.05197 | 0.08 | 0.78 | 0.823 | 0.34 | 0.13 |
Prepaid Expenses | 0.06522 | 0.061 | 0.369 | 0.047 | 0.064 | 0.084 |
Total Assets | 1.87295 | 1.802 | 18.339 | 9.053 | 28.095 | 45.551 |
Property/Plant/Equipment, Total - Net | 0.0194 | 0.037 | 0.096 | 0.217 | 0.174 | 0.112 |
Property/Plant/Equipment, Total - Gross | 0.0422 | 0.26 | 0.231 | 0.179 | ||
Accumulated Depreciation, Total | -0.0228 | -0.043 | -0.057 | -0.067 | ||
Total Current Liabilities | 0.62697 | 1.003 | 1.296 | 1.318 | 2.028 | 1.524 |
Accounts Payable | 0.32663 | 0.182 | 1.099 | 0.509 | ||
Accrued Expenses | 0.24533 | 1.13 | 0.923 | 1.011 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.05501 | 0.084 | 0 | |||
Total Liabilities | 0.62697 | 1.003 | 1.314 | 1.436 | 2.081 | 1.527 |
Total Long Term Debt | 0 | 0 | 0.018 | 0.013 | 0.007 | 0.003 |
Other Liabilities, Total | 0 | 0.105 | 0.046 | 0 | ||
Total Equity | 1.24599 | 0.799 | 17.025 | 7.617 | 26.014 | 44.024 |
Common Stock | 40.9937 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 6.21111 | 41.033 | 62.993 | 64.232 | 94.925 | 126.576 |
Retained Earnings (Accumulated Deficit) | -46.5459 | -40.234 | -45.968 | -56.617 | -68.909 | -82.501 |
Other Equity, Total | 0.58708 | 0.002 | -0.002 | -0.051 | ||
Total Liabilities & Shareholders’ Equity | 1.87295 | 1.802 | 18.339 | 9.053 | 28.095 | 45.551 |
Total Common Shares Outstanding | 5.52605 | 6.37066 | 11.9569 | 12.0069 | 18.7462 | 26.4431 |
Accounts Receivable - Trade, Net | 0.08 | 0.78 | 0.13 | |||
Other Long Term Assets, Total | 0.271 | 0.271 | 0 | |||
Payable/Accrued | 0.919 | 1.291 | ||||
Current Port. of LT Debt/Capital Leases | 0 | 0.005 | 0.006 | 0.006 | 0.004 | |
Capital Lease Obligations | 0 | 0.018 | 0.013 | 0.007 | 0.003 | |
Short Term Investments | 3.995 | 20.098 | 40.405 | |||
Other Current Assets, Total | 0.088 | 0.01 | 0.113 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 24.195 | 21.629 | 48.537 | 45.439 | 42.111 |
Cash and Short Term Investments | 23.401 | 21.295 | 48.097 | 45.112 | 41.047 |
Cash | 3.329 | 2.228 | 16.219 | 4.707 | 3.032 |
Short Term Investments | 20.072 | 19.067 | 31.878 | 40.405 | 38.015 |
Total Receivables, Net | 0.337 | 0.016 | 0.104 | 0.13 | 0.168 |
Prepaid Expenses | 0.457 | 0.318 | 0.336 | 0.084 | 0.793 |
Total Assets | 24.356 | 21.774 | 48.664 | 45.551 | 42.211 |
Property/Plant/Equipment, Total - Net | 0.161 | 0.145 | 0.127 | 0.112 | 0.1 |
Property/Plant/Equipment, Total - Gross | 0.209 | 0.199 | 0.187 | 0.179 | 0.162 |
Accumulated Depreciation, Total | -0.048 | -0.054 | -0.06 | -0.067 | -0.062 |
Total Current Liabilities | 1.178 | 1.44 | 1.624 | 1.524 | 1.434 |
Accounts Payable | 0.689 | 0.239 | 0.699 | 0.509 | 0.433 |
Accrued Expenses | 0.483 | 1.196 | 0.921 | 1.011 | 0.995 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.006 | 0.005 | 0.004 | 0.004 | 0.006 |
Total Liabilities | 1.211 | 1.456 | 1.628 | 1.527 | 1.443 |
Total Long Term Debt | 0.005 | 0.005 | 0.004 | 0.003 | 0.009 |
Capital Lease Obligations | 0.005 | 0.005 | 0.004 | 0.003 | 0.009 |
Other Liabilities, Total | 0.028 | 0.011 | 0 | 0 | |
Total Equity | 23.145 | 20.318 | 47.036 | 44.024 | 40.768 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 95.68 | 96.126 | 126.296 | 126.576 | 126.884 |
Retained Earnings (Accumulated Deficit) | -72.531 | -75.805 | -79.255 | -82.501 | -86.009 |
Other Equity, Total | -0.004 | -0.003 | -0.005 | -0.051 | -0.107 |
Total Liabilities & Shareholders’ Equity | 24.356 | 21.774 | 48.664 | 45.551 | 42.211 |
Total Common Shares Outstanding | 18.7862 | 18.7862 | 26.4392 | 26.4431 | 26.4431 |
Accounts Receivable - Trade, Net | 0.13 | 0.166 | |||
Other Current Assets, Total | 0.113 | 0.103 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -2.22314 | -4.26 | -5.734 | -10.649 | -12.292 | -13.592 |
Cash From Operating Activities | -3.02318 | -3.9 | -5.696 | -9.102 | -9.185 | -12.252 |
Cash From Operating Activities | 0.0022 | 0.004 | 0.015 | 0.021 | 0.021 | 0.024 |
Non-Cash Items | 0.14174 | 0.4 | 0.659 | 1.139 | 1.891 | 1.777 |
Cash Interest Paid | 0.02552 | 0.002 | 0.002 | |||
Changes in Working Capital | -0.94397 | -0.044 | -0.636 | 0.387 | 1.195 | -0.461 |
Cash From Investing Activities | -0.00689 | -0.022 | -0.05 | -3.908 | -16.134 | -20.537 |
Capital Expenditures | -0.00689 | -0.022 | -0.05 | -0.002 | -0.047 | -0.022 |
Cash From Financing Activities | 4.59263 | 3.539 | 21.216 | 0.07 | 28.845 | 30.087 |
Issuance (Retirement) of Stock, Net | 4.59263 | 3.539 | 21.216 | 0.075 | 28.85 | 30.093 |
Foreign Exchange Effects | 0.00767 | |||||
Net Change in Cash | 1.57023 | -0.383 | 15.47 | -12.94 | 3.526 | -2.702 |
Cash Taxes Paid | 0.026 | 0.036 | 0.028 | |||
Other Investing Cash Flow Items, Total | -3.906 | -16.087 | -20.515 | |||
Issuance (Retirement) of Debt, Net | -0.005 | -0.005 | -0.006 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.622 | -6.896 | -10.346 | -13.592 | -3.508 |
Cash From Operating Activities | -4.313 | -6.402 | -9.448 | -12.252 | -3.888 |
Cash From Operating Activities | 0.006 | 0.012 | 0.018 | 0.024 | 0.006 |
Non-Cash Items | 0.551 | 1.023 | 1.354 | 1.777 | 0.443 |
Changes in Working Capital | -1.248 | -0.541 | -0.474 | -0.461 | -0.829 |
Cash From Investing Activities | -0.009 | 0.98 | -11.848 | -20.537 | 2.214 |
Capital Expenditures | -0.009 | -0.013 | -0.015 | -0.022 | 0 |
Other Investing Cash Flow Items, Total | 0 | 0.993 | -11.833 | -20.515 | 2.214 |
Cash From Financing Activities | 0.242 | 0.241 | 30.106 | 30.087 | -0.001 |
Issuance (Retirement) of Stock, Net | 0.244 | 0.244 | 30.111 | 30.093 | 0 |
Issuance (Retirement) of Debt, Net | -0.002 | -0.003 | -0.005 | -0.006 | -0.001 |
Net Change in Cash | -4.08 | -5.181 | 8.81 | -2.702 | -1.675 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9597 | 782640 | 0 | 2022-09-30 | LOW |
Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
Jacob Asset Management of New York, LLC | Investment Advisor | 0.9019 | 238500 | 0 | 2022-09-30 | LOW |
Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
Lynch (Timothy Patrick) | Individual Investor | 0.7573 | 200259 | 0 | 2021-12-31 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7004 | 185219 | 8197 | 2022-09-30 | LOW |
Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2617 | 69198 | -11450 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2455 | 64930 | 2153 | 2022-09-30 | LOW |
Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | LOW |
Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | -15381 | 2022-09-30 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1589 | 42007 | 5207 | 2022-09-30 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.1491 | 39418 | -4531 | 2022-09-30 | HIGH |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group +500000+
Trader
93000+
Klien aktif per bulan
$57000000+
Volume investasi per bulan
$31000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com